Population Pharmacokinetics of Intramuscular Artesunate in African Children With Severe Malaria: Implications for a Practical Dosing Regimen

1] Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand [2] Centre for Tropical Medicine, Churchill Hospital, University of Oxford, Oxford, UK.
Clinical Pharmacology &#38 Therapeutics (Impact Factor: 7.9). 02/2013; 93(5). DOI: 10.1038/clpt.2013.26
Source: PubMed


Parenteral artesunate (ARS) is the drug of choice for the treatment of severe malaria. Pharmacokinetics data on intramuscular ARS are limited with respect to the main treatment group that carries the highest mortality, namely, critically ill children with severe malaria. A population pharmacokinetic study of ARS and dihydroartemisinin (DHA) was conducted from sparse sampling in 70 Tanzanian children of ages 6 months to 11 years. All the children had been admitted with severe falciparum malaria and were treated with intramuscular ARS (2.4 mg/kg at 0, 12, and 24 h). Venous plasma concentration-time profiles were characterized using nonlinear mixed-effects modeling (NONMEM). A one-compartment disposition model accurately described first-dose population pharmacokinetics of ARS and DHA. Body weight significantly affected clearance and apparent volume of distribution (P < 0.001), resulting in lower ARS and DHA exposure levels in smaller children. An adapted dosing regimen including a practical dosing table per weight band is proposed for young children based on the pharmacokinetic model.Clinical Pharmacology & Therapeutics (2013); advance online publication 20 March 2013. doi:10.1038/clpt.2013.26.

Download full-text


Available from: Ilse C E Hendriksen,
  • Source
    • "Some non-steroidal anti-inflammatory drugs (NSAIDs) can retard tumor development via down-regulation of IL-10 and PGE 2 [33] [34] [35], but their well-known toxicities are inevitable [34]. ART may present a therapeutic advantage because it can attack tumor through multiple pathways (e.g., inhibiting tumor cell proliferation, interfering with angiogenesis, enhancing sensitivity to treatment, decreasing toxicity and side-effects of radiotherapy and chemotherapy, etc.), along with nontoxicity, low cost and considerable efficacy [15] [16] [17] [18] [19] [20] [21] [22]. Now, our study revealed a strong and persistent down-regulating effect of ART on immunosuppression and the secretion of TGF-β 1 and IL-10. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Immunosuppression is the main source of ineffective treatment on tumor, and the study aimed to investigate the effect of artesunate on tumor immunosuppression. Supernatants of re-cultivated murine colorectal cancer cell Colon26 and human colorectal cancer cell RKO after pre-treatment with or without artesunate were enrolled, and their effects on five immune parameters were assessed, including killing activity of natural killer (NK) and lymphocyte proliferation, as measured by MTT, and expressions of interleukin 2 receptor (IL-2R)α, CD3ε(+)ζ(+) and CD3ε(-)ζ(+) on lymphocytes, as analyzed by flow cytometry. Six immunosuppressive factors were measured by ELISA, including transforming growth factor (TGF) β1, vascular endothelial growth factor (VEGF), IL-4, IL-6, IL-10, and prostaglandin E2 (PGE2). Then, multiple linear regression analysis was applied to reveal the correlation between immunosuppression and immunosuppressive factors, and was used to confirm the findings. It was shown that Colon26 and RKO cells secreted immunosuppressive factors and inhibited these five immune parameters steadily. After pretreatment with artesunate, immunosuppression from the two cells was down-regulated significantly (all P<0.05), and the concentrations of TGF-β1 and IL-10 decreased greatly (all P<0.001). There were positive correlations between the down-regulation of immunosuppression and the decrease in TGF-β1 or IL-10. Their combined potency attributed to decreased TGF-β1 and IL-10 with respect to the down-regulating effect of artesunate on immunosuppression of NK killing, lymphocyte proliferation and expressions of IL-2Rα and CD3ε(+)ζ(+), was about 60%-90%. The present analysis provides clues that artesunate reverses the immunosuppression from Colon26 and RKO colorectal cancer cells by decreasing TGF-β1 and IL-10. This is probably one of the anti-tumor mechanisms of artesunate. Copyright © 2015. Published by Elsevier B.V.
    International immunopharmacology 07/2015; 27(1). DOI:10.1016/j.intimp.2015.05.004 · 2.47 Impact Factor
  • Source
    • "Proposed body weight-adjusted dosing for intramuscular artesunate [18]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Severe malaria kills more than a half million people each year. Based on high-quality evidence of the efficacy superiority of artesunate over quinine in adults and children with severe malaria, the World Health Organization guidelines have been revised. The WHO currently recommends injectable artesunate as the first-line treatment for severe malaria. Since this revision in April 2011, only a small number of countries affected by malaria have adopted and implemented the new policy. If this policy is implemented, an additional 195,000 lives would be saved each year in Africa. Thus, there is an urgent need to speed up access to injectable artesunate in malaria-endemic countries. This review presents a background for recommending artesunate as the first-line treatment of severe malaria in children and adults, and interventions that are recommended to accelerate access to injectable artesunate.
    Journal of Infection and Public Health 09/2014; 7(5). DOI:10.1016/j.jiph.2014.04.007
  • Source
    • "The currently recommended parenteral dose is twice this and is the same as the recommended initial dose, 2.4 mg/kg/day (1, 15, 16). Recent evidence suggests that this dose should be increased in young children (17). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Antimalarial drugs have usually been first deployed in endemic areas at doses which were too low, particularly for high risk groups such as young children and pregnant women. This may accelerate the emergence and spread of resistance, thereby shortening the useful life of the drug, but it is an inevitable consequence of the current imprecise method of dose-finding. An alternative approach to dose-finding is suggested in which phase 2 studies concentrate initially on pharmacokinetic-pharmacodynamic (PK-PD) characterization and in-vivo calibration of in-vitro susceptibility information. PD assessment is facilitated in malaria because serial parasite densities are readily assessed by microscopy, and at low densities by quantitative PCR, so initial therapeutic responses can be quantitated accurately. If the in-vivo minimum inhibitory concentration (MIC) can be characterized early in phase 2 studies it would provide a sound basis for the choice of dose in all target populations in subsequent combination treatments. Population PK assessments in phase 2b and phase 3 studies which characterize PK differences between different age groups, clinical disease states, and human populations can then be combined with the PK-PD observations to provide a sound evidence base for dose recommendations in different target groups.
    Antimicrobial Agents and Chemotherapy 09/2013; 57(12). DOI:10.1128/AAC.00287-13 · 4.48 Impact Factor
Show more

We use cookies to give you the best possible experience on ResearchGate. Read our cookies policy to learn more.